inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 701–800 of 1,000
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Woods, G. L., Lin, S.-Y. G., & Desmond, E. P. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch76 · Cited by 25
The katE gene, which encodes the catalase HPII of Mycobacterium avium
Milano, A., Rossi, E. D., Gusberti, L., Heym, B., Marone, P., & Riccardi, G. (1996) · Molecular Microbiology · doi:10.1046/j.1365-2958.1996.352876.x · Cited by 24
Gurvitz, A., Hiltunen, J. K., & Kastaniotis, A. J. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.00655-08 · Cited by 26
“The primary target of INH is InhA (3), and this fact alone elevates InhA to the position of one of most medically significant pathogen proteins.”
BackgroundMethodRecent advances towards identification of new drug targets for Mycobacterium tuberculosis
Sharma, K., Chopra, P., & Singh, Y. P. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.2.79 · Cited by 24
“ETA Inhibition of mycolic acid synthesis Acyl carrier protein reductase (InhA) [11]”
BackgroundKanetaka, H., Koseki, Y., Taira, J., Umei, T., Komatsu, H., Sakamoto, H., Gülten, G., Sacchettini, J. C., Kitamura, M., & Aoki, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.02.062 · Cited by 23
Brossier, F., Boudinet, M., Jarlier, V., Petrella, S., & Sougakoff, W. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.06.002 · Cited by 28
“mutation in KatG) [8-10], and secondarily to mutations in the InhA protein, which prevent the 108 activated forms of the drug to bind to the target [3, 5], and in the inhA promoter that cause 109 overexpression of the target InhA [6, 7].”
BackgroundIdentification of Inhibitors of Fungal Fatty Acid Biosynthesis
DeJarnette, C. A., Meyer, C. J., Jenner, A. R., Butts, A., Peters, T. L., Cheramie, M. N., Phelps, G. A., Vita, N. A., Loudon, V. C., Lee, R. E., Jr., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00404 · Cited by 25
Paz, J. D., Sperotto, N. D. D. M., Ramos, A. S., Pissinate, K., Rodrigues-Junior, V. S., Abbadi, B. L., Borsoi, A. F., Rambo, R. S., Minotto, A. C. C., Dadda, A. D. S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114908 · Cited by 24
Engineered Biosensors for Diagnosing Multidrug Resistance in Microbial and Malignant Cells
Jha, N. G., Dkhar, D. S., Singh, S. K., Malode, S. J., Shetti, N. P., & Chandra, P. (2023) · Biosensors · doi:10.3390/bios13020235 · Cited by 24
Rani, C., Mehra, R., Sharma, R., Chib, R., Wazir, P., Nargotra, A., & Khan, I. A. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.06.003 · Cited by 23
“tuberculosis cell wall components could be a useful tool for discovering new drug like molecules [2,3].”
BackgroundHuman multidrug-resistant Mycobacterium bovis infection in Mexico
Vázquez-Chacón, C. A., Martínez-Guarneros, A., Couvin, D., González-y-Merchand, J. A., Rivera-Gutiérrez, S., Escobar‐Gutiérrez, A., López, J. J. D.-L.-C., Gómez-Bustamante, A., Gonzalez-Macal, G. A., Rossi, L. M. G., et al. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.07.010 · Cited by 23
“Thus, the high degree of resistance to Eto observed among all these TB strains is somehow expected.”
BackgroundSonia, G., & Ravi, T. K. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0340-3 · Cited by 23
“The enzyme, enoyl-acyl carrier protein (ACP) reductase of the Mycobacterium tuberculosis, encoded by the gene InhA, of the type II fatty acid biosynthesis pathway (FASII) is identified as one of the key enzyme for the biosynthesis of mycolic acids (Banerjee et al., 1994).”
Mohanram, I., & Meshram, J. S. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0693-2 · Cited by 23
“Isoniazid has the greatest bactericidal activity and is used almost from the outset of tuberculosis chemotherapy (Banerjee et al., 1994; Deretic et al., 1996; Rozwarski et al., 1998).”
BackgroundHerrera, L., Valverde, A., Sáiz, P. A., Sáez-Nieto, J. A., Portero, J. L., & Jiménez, M. S. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.09.032 · Cited by 23
“[23] identified a locus containing two contiguous open reading frames (designed orf1 and inhA) coding for products that may participate in resistance to both INH and ETH.”
BackgroundMultidrug-resistant tuberculosis
Lemos, A. C. M., & Matos, E. D. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.01.007 · Cited by 39
Bhowruth, V., Brown, A. K., & Besra, G. S. (2008) · Microbiology · doi:10.1099/mic.0.2008/017434-0 · Cited by 24
Pitso, L., Potgieter, S. T., & van Dijk, A. V. D. S. (2019) · South African Medical Journal · doi:10.7196/samj.2019.v109i9.13730 · Cited by 23
Singh, A., Gupta, A. K., & Singh, S. (2020) · Springer eBooks · doi:10.1007/978-981-32-9898-9_12 · Cited by 29
Chemical Exchanges between Multilateral Symbionts
Bae, M., Mevers, E. E., Pishchany, G., Whaley, S., Rock, C. O., Andes, D. R., Currie, C. R., Pupo, M. T., & Clardy, J. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c00068 · Cited by 23
Zhang, S. ‐., Shen, J.-G., Xu, P.-H., Li, D.-X., Sun, Z.-Q., Li, L., Yang, Z.-R., & Sun, Q. (2007) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2007.03350.x · Cited by 26
“2004); the other 20–35% of INH-resistant strains contain mutations in inhA regulatory region (Banerjee et al. 1994; Telenti et al. 1997) and an additional 10–15% have mutations in the oxyR-ahpC intergenic region (Kelley et al.”
BackgroundDomenech, P., Honoré, N., Heym, B., & Cole, S. T. (2001) · Microbes and Infection · doi:10.1016/s1286-4579(01)01422-8 · Cited by 25
Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis
Telenti, A., & Persing, D. H. (1996) · Research in Microbiology · doi:10.1016/0923-2508(96)80207-5 · Cited by 23
Biodegradation of Picolinic Acid by a Newly Isolated Bacterium Alcaligenes faecalis Strain JQ135
Qiu, J., Zhang, J., Zhang, Y., Wang, Y., Tong, L., Hong, Q., & He, J. (2017) · Current Microbiology · doi:10.1007/s00284-017-1205-2 · Cited by 22
Kienle, M., Eisenring, P., Stoessel, B., Horlacher, O. P., Hasler, S., van Colen, G., Hartkoorn, R. C., Vocat, A., Cole, S. T., & Altmann, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01457 · Cited by 22
Wijesundera, S. A., Jayawardana, K. W., & Yan, M. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c02047 · Cited by 22
Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design
Reshma, R. S., Daher, S. S., Gallardo‐Macias, R., Wang, X., Neiditch, M. B., & Freundlich, J. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1008213 · Cited by 26
“For instance, isoxyl and thioacetazone are known to target the HadAB/HadBC (3R)-hydroxyacyl-ACP dehydratase complex, whereas isoniazid and ethionamide prevent the reduction of enoyl-AcpM by targeting InhA (Banerjee et al., 1994; Vilcheze et al., 2006).”
BackgroundEngström, A. (2015) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2015.1061205 · Cited by 25
Sellar-Suprasellar Tuberculomas in Children: 2 Cases and Literature Review
Nayil, K., Singh, S., Makhdoomi, R. H., Ramzan, A., & Wani, A. A. (2011) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2011.01.020 · Cited by 22
Reich‐Slotky, R., Kabbash, C. A., Della‐Latta, P., Blanchard, J. S., Feinmark, S. J., Freeman, S. L., Kaplan, G., Shuman, H. A., & Silverstein, S. C. (2009) · Journal of Bacteriology · doi:10.1128/jb.00175-09 · Cited by 23
“Using this strategy, we identified a 1,375-bp fragment from L. pneumophila which complemented the FT100 TS strain for growth at 42°C. Sequence analysis of this 1,375-bp DNA fragment demonstrated that it includes an 804-bp open reading frame (GenBank accession number AE017354; lpg1854) (10) encoding a putative 268-amin…”
BackgroundInfluentialNorcott, P., Rayner, P. J., Green, G. G. R., & Duckett, S. B. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201703278 · Cited by 22
Suresh, A., Srinivasarao, S., Napiórkowska, A., AUGUSTYNOWICZ-KOPEĆ, E. M., Alvala, M., Lherbet, C., & Sekhar, K. V. G. C. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13127 · Cited by 22
Jagadeb, M., Rath, S. N., & Sonawane, A. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1515116 · Cited by 22
“According to the WHO global tuberculosis report 2017 (http://www.who.int/tb/publications/global_ report/en/), a total of 490,000 MDR-TB has been reported worldwide in 2016 and approximately 47% of these cases were reported from India, China and the Russian Federation.”
BackgroundInfluentialCell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis
McNeil, M. B., Chettiar, S. N., Awasthi, D., & Parish, T. (2019) · Access Microbiology · doi:10.1099/acmi.0.000006 · Cited by 25
“5 ethambutol (arabinosyl transferase inhibitor) [12], INH (InhA inhibitor) [13] and 67 thiophene-2 (Pks13 inhibitor) [14] resulted in at least a four-fold increase in RIF-FITC 68 accumulation (Figure 2c).”
BackgroundMycolic Acids: From Chemistry to Biology
Daffé, M., Quémard, A., & Marrakchi, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-43676-0_18-1 · Cited by 34
Lu, X., Chen, Y., Jiang, Y., & You, Q. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.03.043 · Cited by 23
Orme, I. M. (1999) · Elsevier eBooks · doi:10.1016/b978-012775390-4/50174-3 · Cited by 22
New strategies in the treatment of avian mycobacteriosis
VanDerHeyden, N. (1997) · Seminars in Avian and Exotic Pet Medicine · doi:10.1016/s1055-937x(97)80038-2 · Cited by 22
Antimycobacterial susceptibility testing: Present practices and future trends
Inderlied, C. B. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02111499 · Cited by 22
“Banerjee et al. ( 72 ) recently reported that isoniazid and ethionamide resistance in Mycobacterium tuberculosis correlates with a missense mutation in the inhA gene.”
BackgroundA Waxy Tale, by Mycobacterium tuberculosis
Kremer, L., & Besra, G. S. (2004) · Wiley eBooks · doi:10.1128/9781555817657.ch19 · Cited by 36
Molecular Dynamics Simulations in Drug Discovery
Choi, S. B., Yap, B. K., Choong, Y. S., & Wahab, H. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20154-4 · Cited by 27
Puniya, B. L., Kulshreshtha, D., Verma, S. P., Kumar, S., & Ramachandran, S. (2013) · Molecular BioSystems · doi:10.1039/c3mb70278b · Cited by 22
Wondale, B., Medhin, G., Abebe, G., Tolosa, S., Mohammed, T., Teklu, T., Pieper, R., & Ameni, G. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s165088 · Cited by 27
Differential Expression of Resistant and Efflux Pump Genes in MDR-TB Isolates
AlMatar, M., Var, İ., Kayar, B., & Köksal, F. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191009153834 · Cited by 26
Al-Khattaf, F. S., Mani, A., Hatamleh, A. A., & Idhayadhulla, A. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.12.033 · Cited by 21
Barozi, V., Musyoka, T. M., Amamuddy, O. S., & Bishop, Ö. T. (2022) · ACS Omega · doi:10.1021/acsomega.2c01036 · Cited by 22
Rajalakshmi, G., Pavan, M. S., & Kumaradhas, P. (2014) · RSC Advances · doi:10.1039/c4ra07953a · Cited by 21
Gomez, A., Andreu, N., Ferrer‐Navarro, M., Yero, D., & Gibert, I. (2016) · Scientific Reports · doi:10.1038/srep26221 · Cited by 22
“Gentamycin 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3)”
Johansen, M. D., Shalini, S., Kumar, S., Raynaud, C., Quan, D. H., Britton, W. J., Hansbro, P. M., Kumar, V., & Kremer, L. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00011-21 · Cited by 24
“smegmatis mc2651, a strain harboring the S94A mutation in InhA (10), compared to the parental strain mc2155 in liquid culture (Table 3) and on solid me-”
BackgroundInfluentialRafidinarivo, E., Lanéelle, M., Montrozier, H. L., Valero-Guillén, P. L., Astola, J., Luquin, M., Promé, J., & Daffé, M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800384-jlr200 · Cited by 21
Antimycobacterial Activity and Mechanism of Action of NAS-91
Gratraud, P., Surolia, N., Besra, G. S., Surolia, A., & Kremer, L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00968-07 · Cited by 21
“Thiolactomycin inhibits the -ketoacyl ACP synthases KasA and KasB (11), whereas isoniazid (INH) and ethionamide inhibit the enoyl-ACP reductase InhA (1, 23); KasA/KasB and InhA are enzymes that catalyze the first and last steps of the repetitive FAS-II cycle, respectively.”
BackgroundAndreu, N., Soto, C. Y., Roca, I., Martı́n, C., & Gibert, I. (2004) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(04)00008-4 · Cited by 22
“This approach has been used successfully to identify some targets for anti-tuberculosis drugs [7,8] as well as genes that enhance mycobacterial survival in macrophages [9,10].”
MethodOver-expression of target genes as a mechanism of antibiotic resistance in bacteria
Chopra, I. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.6.584 · Cited by 23
Knipfer, N., Seth, A., & Shrader, T. E. (1997) · Plasmid · doi:10.1006/plas.1997.1286 · Cited by 21
Molecular biology in the diagnosis and epidemiology of tuberculosis
Drobniewski, F. A., Kent, R., Stoker, N. G., & Uttley, A. H. C. (1994) · Journal of Hospital Infection · doi:10.1016/0195-6701(94)90089-2 · Cited by 24
Expression of Foreign Genes in Mycobacteria
Burlein, J. E., Stover, C. K., Offutt, S., & Hanson, M. S. (2014) · ASM Press eBooks · doi:10.1128/9781555818357.ch17 · Cited by 21
Hu, X., Li, X., Huang, L., Chan, J., Chen, Y., Deng, H., & Mi, K. (2015) · Journal of Proteome Research · doi:10.1021/pr5011058 · Cited by 21
Lyonnet, B. B., Diacovich, L., Gago, G., Spina, L., Bardou, F., Lemassu, A., Quémard, A., & Gramajo, H. C. (2017) · FEBS Journal · doi:10.1111/febs.14046 · Cited by 23
Akpobolokemi, T., Martínez-Nuñez, R. T., & Raimi‐Abraham, B. T. (2022) · The Journal of Medicine Access · doi:10.1177/23992026211070406 · Cited by 25
Molecular Basis of Rhodomyrtone Resistance in Staphylococcus aureus
Huang, L. F., Matsuo, M., Calderón, C., Fan, S., Ammanath, A. V., Fu, X., Li, N., Luqman, A., Wenninger, M. K., Herrmann, F., et al. (2022) · mBio · doi:10.1128/mbio.03833-21 · Cited by 20
“The second main cause of resistance to isoniazid (INH) is the overexpression of enoyl-acyl-carrier protein reductase InhA (34, 35).”
BackgroundHow Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
Bhagwat, A., Deshpande, A., & Parish, T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.974101 · Cited by 20
“The activated molecule forms an adduct with NAD(H) at the active site of the enzyme (Banerjee et al., 1994; Rawat et al., 2003).”
BackgroundEfficacy and Mode of Action of a Direct Inhibitor of Mycobacterium abscessus InhA
Alcaraz, M., Roquet, F., Leon‐Icaza, S. A., Abendroth, J. A., Boudehen, Y., Cougoule, C., Edwards, T. E., & Kremer, L. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00314 · Cited by 29
Gong, Y., Wei, C., Wang, J., Mu, N., Lu, Q., Wu, C., Yan, N., Yang, H., Zhao, Y., Yang, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302858120 · Cited by 21
Shao, Z., Tam, K. K.-G., Achalla, V. P. K., Woon, E. C. Y., Mason, A. J., Chow, S. F., Yam, W. C., & Lam, J. K. W. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123960 · Cited by 20
Drug Resistant Mycobacterium tuberculosis in Benue, Nigeria
Nwadioha, S. I. (2014) · British Microbiology Research Journal · doi:10.9734/bmrj/2014/9084 · Cited by 20
Cohen‐Gonsaud, M., Ducasse-Cabanot, S., Quémard, A., & Labesse, G. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20494 · Cited by 20
Ang, M. L. T., Siti, Z. Z. R., Shui, G., Dianišková, P., Madacki, J., Lin, W., Koh, V. H. Q., Gómez, J. M. M., Sudarkodi, S., Bendt, A. K., et al. (2014) · Infection and Immunity · doi:10.1128/iai.01332-13 · Cited by 22
“involved in mycolic acid (MA) synthesis (13, 14).”
BackgroundCarboxylate Surrogates Enhance the Antimycobacterial Activity of UDP-Galactopyranose Mutase Probes
Winton, V. J., Aldrich, C., & Kiessling, L. L. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00021 · Cited by 21
Mycolic Acids: From Chemistry to Biology
Daffé, M., Quémard, A., & Marrakchi, H. (2019) · Springer eBooks · doi:10.1007/978-3-319-50430-8_18 · Cited by 24
Li, H., Yuan, J., Duan, S., & Pang, Y. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1573 · Cited by 22
A Novel Interaction Linking the FAS-II and Phthiocerol Dimycocerosate (PDIM) Biosynthetic Pathways
Kruh‐Garcia, N. A., Borgaro, J. G., Ruzsicska, B. P., Xu, H., & Tonge, P. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802169200 · Cited by 20
Five-antituberculosis Drug-resistance Genes Detection Using Array System
Shimizu, Y., Dobashi, K., Yoshikawa, Y., YABE, S., Higuchi, S., Koike, Y., Mita, Y., Utsugi, M., Endou, K., Takahashi, K., et al. (2008) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.2008033 · Cited by 22
“Mutations of the inhA [6] and KatG [7] genes of M.”
BackgroundJoshi, S. D., More, U. A., Koli, D., Kulkarni, M. S., Nadagouda, M. N., & Aminabhavi, T. M. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.03.001 · Cited by 20
Cardia, M. C., Distinto, S., Maccioni, E., Plumitallo, A., Sanna, M. L., Saddi, M., & Logu, A. D. (2006) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570430529 · Cited by 20
Ferrazoli, L., Palaci, M., Telles, M. A. D. S., Ueki, S. Y. M., Kritski, A. L., Marques, L. R. M., Ferreira, O. C., & Riley, L. W. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.1.237 · Cited by 20
Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Ahsan, M. J., Ansari, M. Y., Yasmin, S., Jadav, S. S., Kumar, P., Garg, S., Ajay, A., & Khalilullah, H. (2014) · Infectious Disorders - Drug Targets · doi:10.2174/1871526514666140923153329 · Cited by 20
Nair, R. R., Sharan, D., Sebastian, J., Swaminath, S., & Ajitkumar, P. (2019) · Microbiology · doi:10.1099/mic.0.000797 · Cited by 20
Zhao, J., Wei, W., Yan, H., Zhou, Y., Li, Z., Chen, Y., Zhang, C., Zeng, J., Chen, T., & Zhou, L. (2019) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2019.06.003 · Cited by 19
Metabolic Changes of Mycobacterium tuberculosis during the Anti-Tuberculosis Therapy
Bespyatykh, J., Shitikov, E. A., Bespiatykh, D., Guliaev, A. S., Klimina, K. M., Veselovsky, V. A., Arapidi, G. P., Догонадзе, М. З., Zhuravlev, V., Ilina, E. N., et al. (2020) · Pathogens · doi:10.3390/pathogens9020131 · Cited by 21
“It is known that INH resistance is associated with hyperproduction of the target InhA protein [19].”
Background(2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70009-x · Cited by 19
de la Iglesia, A. I., & Morbidoni, H. R. (2006) · PubMed · Cited by 29
González-Thuillier, I., Venegas‐Calerón, M., Garcés, R., von Wettstein‐Knowles, P., & Martínez‐Force, E. (2014) · Planta · doi:10.1007/s00425-014-2162-7 · Cited by 24
Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis
Whitney, J. B., & Wainberg, M. A. (2002) · McGill Journal of Medicine · doi:10.26443/mjm.v6i2.686 · Cited by 19
Cingolani, A., Antinori, A., Sanguinetti, M., Gillini, L., Luca, A. D., Posteraro, B., Ardito, F., Fadda, G., & Ortona, L. (1999) · The Journal of Infectious Diseases · doi:10.1086/314677 · Cited by 19
“drugs, and drug resistance results from changes in several target genes, some of which are still undefined [2-8].”
BackgroundMolecular genetic analysis of enoyl‐acyl carrier protein reductase inhibition by diazaborine
de Boer, G.-J., Pielage, G. J. A., Nijkamp, H. J. J., Slabas, A. R., Rafferty, J. B., Baldock, C., Rice, D. W., & Stuitje, A. R. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01182.x · Cited by 19
“…resistance for diazaborine is quite different from the mechanism of isoniazid resistance of M. tuberculosis ENR (InhA), in which resistant mutations are confined to amino acid residues of the NADH binding pocket and show a decreased affinity for NADH (Banerjee et al., 1994; Rozwarski et al., 1998).”
BackgroundAdaptive Evolution of Geobacter sulfurreducens in Coculture with Pseudomonas aeruginosa
Semenec, L., Vergara, I. A., Laloo, A. E., Petrovski, S., Bond, P. L., & Franks, A. E. (2020) · mBio · doi:10.1128/mbio.02875-19 · Cited by 19
“including diazaborine (47), isoniazid (48), and triclosan (49), and a single amino acid”
BackgroundGenetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia
Narmandakh, E., Tumenbayar, O., Borolzoi, T., Erkhembayar, B., Boldoo, T., Dambaa, N., Burneebaatar, B., Naranbat, N., Mitarai, S., Jav, S., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00537-20 · Cited by 21
“inhA mutations may confer cross-resistance to ethionamide (7, 8).”
BackgroundLi, Q., Huang, C., Mao, L., Shao, B., & Zhu, B. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.021 · Cited by 18
Wang, S., Wang, K., Song, K., Lai, Z. W., Li, P., Li, D., Sun, Y., Mei, Y., Xu, C., & Liao, M. (2024) · Nature Communications · doi:10.1038/s41467-024-51948-9 · Cited by 18
Harris, K. K., Fay, A., Yan, H.-G., Kunwar, P., Socci, N. D., Pottabathini, N., Juventhala, R. R., Djaballah, H., & Glickman, M. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500573z · Cited by 19
Laborde, J., Deraeve, C., Duhayon, C., Pratviel, G., & Bernardes‐Génisson, V. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01561a · Cited by 18
Ali, A., Hasan, Z., Moatter, T., Tanveer, M., & Hasan, R. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540802570519 · Cited by 19
“We found Beijing genotypes to have the highest frequency (67%) of mutations at codon 531, which correlated with previous reports [10,27].”
BackgroundResultWang, J., Hudson, R., & Sintim, H. O. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.62 · Cited by 21
Analysis of isoniazid-resistant transposon mutants of Mycobacterium smegmatis
Billman‐Jacobe, H., Sloan, J., & Coppel, R. L. (1996) · FEMS Microbiology Letters · doi:10.1016/0378-1097(96)00336-9 · Cited by 18
Lu, X., Chen, Y., & You, Q. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00926.x · Cited by 18
“Clinical studies indicate that a significant number of the strains resistant to INH arise from mutations in KatG (6).”
BackgroundO’Donnell, M. R., Larsen, M. H., Brown, T. S., Jain, P., Munsamy, V., Wolf, A., Uccellini, L., Karim, F., de Oliveira, T., Mathema, B., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01834-18 · Cited by 18
Self-citationNew Era of TB Drug Discovery and Its Impact on Disease Management
Zheng, X., & Av‐Gay, Y. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0098-0 · Cited by 15
Rossini, N. D. O., & Dias, M. V. B. (2023) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0261 · Cited by 25
“Most of the mutant enzymes that were biochemically or biophysically characterized so far indicate a decrease in the NADH binding affinity to InhA and consequently to INH-NAD, increasing the turnover of the coenzyme and adduct in the protein active site, which favors the enzymatic catalysis (Banerjee et al., 1994; Whit…”
Chikhale, R. V., Eldesoky, G. E., Kolpe, M. S., Suryawanshi, V. S., Patil, P. C., & Bhowmick, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26802 · Cited by 17
“In this case, both drugs target enoyl-acyl carrier protein reductase (InhA), which is an enzyme necessary for mycolic acid synthesis [17].”
BackgroundJayaraman, M., & Ramadas, K. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107768 · Cited by 17
Tuberculosis: current scenario, drug targets, and future prospects
Bose, P., Harit, A. K., Das, R., Sau, S., Iyer, A. K., & Kashaw, S. K. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02691-5 · Cited by 19
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.